Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab for pediatric extranodal NK/T cell lymphoma
ChiCTR2000033625Phase 3Recruiting
- Sponsor
- Beijing Boren Hospital
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tislelizumab in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Beijing Boren Hospital. Primary endpoints: Pharmacokinetics of tislelizumab, Clinical safety of tislelizumab and 1 more. Started Jun 2020; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on ChiCTR2000033625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033625.